			UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 223 www.uspto.gov	Trademark Office OR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/939,518	08/24/2001	Mark J. Jaroszcski	1372.34	2429
	21901 7590 12/31/2008 SMITH HOPEN, PA		EXAMINER	
			EXAM	INER
SMITH HOPE 180 PINE AVI	N, PA ENUE NORTH		EXAM	
SMITH HOPE	N, PA ENUE NORTH			

 MAIL DATE
 DELIVERY MODE

 12/31/2008
 PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

.

	Application No.	Applicant(s)	
	09/939,518	JAROSZESKI ET AL.	
Office Action Summary	Examiner	Art Unit	
	J. E. Angell 1635	1635	
The MAILING DATE of this communication	on appears on the cover sheet w	ith the correspondence address	5
Period for Reply			
 A SHORTENED STATUTORY PERIOD FOR F WHICHEVER IS LONGER, FROM THE MAILI Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communicat If NO period for reply is specified above, the maximum statutory Failure to reply within the set or extended period for reply will, b Any reply received by the Office later than three months after th earned patent term adjustment. See 37 CFR 1.704(b). 	NG DATE OF THIS COMMUNI CFR 1.136(a). In no event, however, may a ion. period will apply and will expire SIX (6) MOI y statute, cause the application to become A	CATION. reply be timely filed NTHS from the mailing date of this commun BANDONED (35 U.S.C. § 133).	·
Status			
1) Responsive to communication(s) filed on	02 Sentember 2008		
	This action is non-final.		
3) Since this application is in condition for a	-	ters, prosecution as to the mer	its is
closed in accordance with the practice u	•	••	
Disposition of Claims			
4)⊠ Claim(s) <u>1,2,6,8,10,21,22 and 24-28</u> is/a	•		
4a) Of the above claim(s) is/are wi	thdrawn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) <u>1,2,6,8,10,21,22 and 24-28</u> is/a	re rejected.		
7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction	and/or election requirement.		
Application Papers			
9) The specification is objected to by the Ex	aminer.		
10) The drawing(s) filed on is/are: a)] accepted or b)] objected to	by the Examiner.	
Applicant may not request that any objection	to the drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the	correction is required if the drawing	g(s) is objected to. See 37 CFR 1.7	121(d)
11) The oath or declaration is objected to by	the Examiner. Note the attache	d Office Action or form PTO-18	52.
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for fo	preign priority under 35 U.S.C.	§ 119(a)-(d) or (f).	
a) All b) Some * c) None of:			
1. Certified copies of the priority docu	uments have been received.		
2. Certified copies of the priority docu	uments have been received in A	Application No	
3. Copies of the certified copies of th	e priority documents have beer	n received in this National Stag	е
application from the International E	Bureau (PCT Rule 17.2(a)).		
* See the attached detailed Office action for	a list of the certified copies no	t received.	
Attachment(s)			
1) Notice of References Cited (PTO-892)		Summary (PTO-413)	
 Notice of Draftsperson's Patent Drawing Review (PTO-9 Information Disclosure Statement(s) (PTO/SB/08) 		(s)/Mail Date Informal Patent Application	
	-,	······································	

•

DETAILED ACTION

Claims 1, 2, 6, 8, 10, 21, 22, 24-28 are currently pending and are addressed herein.

Applicants appealed the rejection of the instant claims under 35 U.S.C. 102(e) as being anticipated by Dimmer (U.S. Patent 6,678,558 B1) to The Board of Patent Appeals and Interferences (hereafter "The Board"). The Board rendered a decision on September 2, 2008, reversing the rejection. The Board did not submit comment on the instant claims being obvious over the teaching of Dimmer when used in combination with another reference, such as Hofmann (see below). In light of The Board's decision, and upon further consideration of the claims and Dimmer, the instant Action is deemed appropriate and does not conflict with the Board's decision.

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

2. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 1, 2, 6, 8, 10, 21, 22, 24-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hofmann et al. (U.S. Patent 6,055,453, previously of record) in view of Dimmer et al. (U.S. Patent 6,678,558 B1, previously of record).

Hofmann teaches a method for facilitating a delivery of a desired molecule such as nucleic acids, antisense nucleic acids, Ribozymes, polypeptides, and polynucleotides into a target tissue comprising a cell (see col. 12, lines 14 and 34; col. 13, lines 13, 24 and 31-31); and applying a single continuous electric field to the target tissue for a duration sufficient to effect a change in porosity of the cell of the target tissue sufficient to facilitate entry of a desired molecule into an interior of a cell (for example, see column 10, lines 3-56; and col. 11, lines 63-65). Hofmann explicitly teaches that there can be any "number of desired pulses, typically one to 100 pulses per second." (See column 10, lines 12-13). Hofmann explicitly teaches that the electric field can have a field strength comprising 10V/cm-20kV/cm and can be applied for a duration of 10µs-100ms (see col. 10, lines 3-41). Hofmann teaches that the electric field can be, for example, a square pulse waveform (see col.10, line 55-56). Hofmann teaches that the introducing step can be by needle injection (i.e. syringe) (see col. 13, lines 31-45). Hofmann also teaches that the target tissue can be skin, tumor, muscle, ovary, prostate, lung, heart, kidney, colon, testis, melanoma, etc. (see col. 14, lines 10-30). Hofmann also specifically teaches, "In a particular embodiment, it is preferred that when the electric field is low, the pulse length is long." (See column 10, lines 37-39).

Hofmann does not teach applying the pulse for a duration of longer than 100ms.

Similarly, Dimmer teaches a method for delivering an agent such as a nucleic acid into a cell of a target tissue (such as skin or tumor tissue) using an electric signal (e.g., see abstract), wherein the agent is injected directly by needle and syringe (e.g., see column2 lines 24-27), wherein the electric signal can have a bipolar, square or sinusoidal waveform (e.g., see column 5, lines 35-36; column 8, lines 17-30), wherein the electric field(s) are in the range of 1mV/cm to 200V/cm (e.g., 25V/cm or 100V/cm see column 10, lines 29-42). Importantly, Dimmer teaches:

The efficiency of cell electroporation increases as the energy field between the electrodes 16 increases. The energy field created between two electrodes 16 can be determined according to Equation 2, where E is the electric field, V is the potential between the two electrodes 16, r is the diameter of an electrode and D is the displacement between the electrode centers.

 $E=V/(2r \ln(D/r))$ (2) (See column 10, lines 20-27);

As the electric field increases, the total electroporation signal duration can be decreased in order to prevent excessive amounts of energy from being delivered to the treatment site 30. The total electroporation signal duration is preferably less than about 10 seconds, more preferably about 30µs-10 seconds, even more preferably about 30µs-1ms and most preferably about 50µs-400ms. (See column 20, lines 38-44);

Claim 5 of Dimmer reads: "A method according to claim 1 wherein the

therapeutic electric signal is comprised of 1 to about 1,000,000 pulses."

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made combine the teachings of Hofmann and Dimmer to create the claimed invention wherein application of a single continuous electric field in the range of 1V/cm to 200 V/cm is applied for a duration in the range of 200ms to 20 minutes can effect a change in the porosity of a cell sufficient to facilitate entry of a desired molecule into an interior of the cell, with a reasonable expectation of success.

Hofmann provides an explicit teaching that when low electric fields are used, longer pulses should be used. Specifically Hofmann teaches, "[I]t is preferred that when the electric field is low, the pulse length is long." (See column 10, lines 37-39). Therefore, Hofmann provides a motivation to use low electric fields for longer durations of time. Furthermore, since Hofmann teaches that applying an electric field within the claimed range for a duration of 100ms is sufficient to change the porosity of a cell membrane to allow entry of a molecule into a cell, it would be expected that increasing the length of the pulse to more than 200ms and up to 10 seconds would also be sufficient to facilitate entry of a molecule into a cell.

Therefore, the instant claims are considered to be obvious in view of the teachings of Hofmann and Dimmer.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. E. Angell whose telephone number is 571-272-0756. The examiner can normally be reached on Monday-Thursday 8:00 a.m.-6:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Douglas Schultz can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/J. E. Angell/ Primary Examiner, Art Unit 1635